CoChat
Sign Up
Cited by 94

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables

Lee, Ellen E., Hong, Suzi, Martin, Averria Sirkin, Eyler, Lisa T., Jeste, Dilip V.·2017·The American Journal of Geriatric Psychiatry
DOI 10.1016/j.jagp.2016.09.009PMC PMC5164855
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jagp.2016.09.009

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 11 references

Research works printed but not linked: 103

  1. Hennekens, 2005, Schizophrenia and increased risks of cardiovascular disease, Am Heart J, 150, 1115, 10.1016/j.ahj.2005.02.007 · DOI · Paper page
  2. Saha, 2007, A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?, Arch Gen Psychiatry, 64, 1123, 10.1001/archpsyc.64.10.1123 · DOI · Paper page
  3. Jeste, 2011, Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia, Schizophr Bull, 37, 451, 10.1093/schbul/sbr026 · DOI · Paper page
  4. Nasrallah, 2015, The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: a focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization, Schizophr Res, 166, 69, 10.1016/j.schres.2015.04.031 · DOI
  5. Kirkpatrick, 2008, Is schizophrenia a syndrome of accelerated aging?, Schizophr Bull, 34, 1024, 10.1093/schbul/sbm140 · DOI · Paper page
  6. Ohayon, 2007, Biomarkers and classifications, J Psychiatr Res, 41, 623, 10.1016/j.jpsychires.2007.03.003 · DOI
  7. Dickerson, 2016, Inflammatory markers in recent onset psychosis and chronic schizophrenia, Schizophr Bull, 42, 134
  8. Miller, 2014, C-reactive protein levels in schizophrenia: a review and meta-analysis, Clin Schizophr Relat Psychoses, 7, 223, 10.3371/CSRP.MICU.020813 · DOI
  9. Maes, 1995, Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers, J Psychiatr Res, 29, 141, 10.1016/0022-3956(94)00049-W · DOI
  10. Naudin, 1996, Elevated circulating levels of IL-6 in schizophrenia, Schizophr Res, 20, 269, 10.1016/0920-9964(96)00014-X · DOI
  11. Lin, 1998, The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6, Schizophr Res, 32, 9, 10.1016/S0920-9964(98)00034-6 · DOI
  12. Mondelli, 2015, Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis, Schizophr Bull, 41, 1162, 10.1093/schbul/sbv028 · DOI · Paper page
  13. Kirkpatrick, 2013, Inflammation and schizophrenia, Schizophr Bull, 39, 1174, 10.1093/schbul/sbt141 · DOI
  14. Iosif, 2006, Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis, J Neurosci, 26, 9703, 10.1523/JNEUROSCI.2723-06.2006 · DOI
  15. O'Brien, 2008, Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia, Psychiatry Res, 160, 256, 10.1016/j.psychres.2007.11.014 · DOI
  16. Brinholi, 2015, Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naive first episode psychosis, Schizophr Res, 166, 225, 10.1016/j.schres.2015.06.009 · DOI
  17. Song, 2013, Elevated levels of adiponectin and other cytokines in drug naive, first episode schizophrenia patients with normal weight, Schizophr Res, 150, 269, 10.1016/j.schres.2013.07.044 · DOI
  18. Pollmacher, 1996, Effects of clozapine on plasma cytokine and soluble cytokine receptor levels, J Clin Psychopharmacol, 16, 403, 10.1097/00004714-199610000-00011 · DOI
  19. Na, 2007, Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia, Neuropsychobiology, 56, 55, 10.1159/000111535 · DOI
  20. Theodoropoulou, 2001, Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients, Schizophr Res, 47, 13, 10.1016/S0920-9964(00)00007-4 · DOI
  21. Monteleone, 1997, Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment, Psychiatry Res, 71, 11, 10.1016/S0165-1781(97)00036-X · DOI
  22. Kowalski, 2001, Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia, Schizophr Res, 50, 169, 10.1016/S0920-9964(00)00156-0 · DOI
  23. Garcia-Miss Mdel, 2010, Folate, homocysteine, interleukin–6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia, J Psychiatr Res, 44, 441, 10.1016/j.jpsychires.2009.10.011 · DOI
  24. Kim, 2009, Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients, Neuropsychobiology, 59, 123, 10.1159/000213565 · DOI
  25. Erbagci, 2001, Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment, Mediators Inflamm, 10, 109, 10.1080/09629350123895 · DOI
  26. Haack, 1999, Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis, J Psychiatr Res, 33, 407, 10.1016/S0022-3956(99)00021-7 · DOI
  27. Xu, 1994, Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia, Br J Psychiatry, 164, 251, 10.1192/bjp.164.2.251 · DOI
  28. Coelho, 2008, Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia, Neuroimmunomodulation, 15, 140, 10.1159/000148197 · DOI
  29. Baker, 1996, Serum cytokine concentrations in patients with schizophrenia, Schizophr Res, 20, 199, 10.1016/0920-9964(95)00089-5 · DOI
  30. Kunz, 2011, Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance, Rev Bras Psiquiatr, 33, 268, 10.1590/S1516-44462011000300010 · DOI
  31. Pedrini, 2012, Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity, J Psychiatr Res, 46, 819, 10.1016/j.jpsychires.2012.03.019 · DOI
  32. Kaminska, 2001, Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients, Arch Immunol Ther Exp (Warsz), 49, 439
  33. Xiong, 2014, Combining serum protein concentrations to diagnose schizophrenia: a preliminary exploration, J Clin Psychiatry, 75, 794, 10.4088/JCP.13m08772 · DOI
  34. Schmitt, 2005, Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication, Neuropsychiatr Dis Treat, 1, 171, 10.2147/nedt.1.2.171.61048 · DOI
  35. Schattner, 1996, No evidence for autoimmunity in schizophrenia, J Autoimmun, 9, 661, 10.1006/jaut.1996.0086 · DOI
  36. Tian, 2014, Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia, Prog Neuropsychopharmacol Biol Psychiatry, 54, 259, 10.1016/j.pnpbp.2014.06.012 · DOI
  37. Francesconi, 2011, Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophrenia, Neurosci Lett, 502, 143, 10.1016/j.neulet.2011.06.042 · DOI
  38. Lv, 2015, Decreased serum TNF-alpha levels in chronic schizophrenia patients on long-term antipsychotics: correlation with psychopathology and cognition, Psychopharmacology (Berl), 232, 165, 10.1007/s00213-014-3650-y · DOI
  39. Al-Asmari, 2014, Inflammation and schizophrenia: alterations in cytokine levels and perturbation in antioxidative defense systems, Hum Exp Toxicol, 33, 115, 10.1177/0960327113493305 · DOI
  40. Dunjic-Kostic, 2013, Serum levels of interleukin–6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia, Psychiatr Danub, 25, 55
  41. Petersen, 2006, The role of IL-6 in mediating the anti-inflammatory effects of exercise, J Physiol Pharmacol, 57, 43
  42. Akiyama, 1999, Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration, Schizophr Res, 37, 97, 10.1016/S0920-9964(98)00140-6 · DOI
  43. Lin, 2011, Increased interleukin-6 level in Taiwanese schizophrenic patients, Chang Gung Med J, 34, 375
  44. Kubistova, 2012, Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls, Psychiatr Danub, 24, S153
  45. An, 2015, Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia, Schizophr Res, 162, 261, 10.1016/j.schres.2014.12.037 · DOI
  46. Beumer, 2012, Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome, Psychoneuroendocrinology, 37, 1901, 10.1016/j.psyneuen.2012.04.001 · DOI
  47. Chang, 2011, Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia, Psychiatry Res, 187, 341, 10.1016/j.psychres.2010.04.049 · DOI
  48. Frydecka, 2015, Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation, Eur Arch Psychiatry Clin Neurosci, 265, 449
  49. Schwieler, 2015, Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia—significance for activation of the kynurenine pathway, J Psychiatry Neurosci, 40, 126, 10.1503/jpn.140126 · DOI
  50. Kalmady, 2014, Relationship between interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naive schizophrenia: evidence for differential susceptibility?, PLoS ONE, 9, e96021, 10.1371/journal.pone.0096021 · DOI
  51. Sasayama, 2013, Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder, J Psychiatr Res, 47, 401, 10.1016/j.jpsychires.2012.12.001 · DOI
  52. Zakharyan, 2012, Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia, Tissue Antigens, 80, 136, 10.1111/j.1399-0039.2012.01886.x · DOI
  53. Fernandez-Egea, 2009, Metabolic profile of antipsychotic-naive individuals with non-affective psychosis, Br J Psychiatry, 194, 434, 10.1192/bjp.bp.108.052605 · DOI
  54. Frommberger, 1997, Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission, Eur Arch Psychiatry Clin Neurosci, 247, 228, 10.1007/BF02900219 · DOI · Paper page
  55. Ganguli, 1994, Serum interleukin–6 concentration in schizophrenia: elevation associated with duration of illness, Psychiatry Res, 51, 1, 10.1016/0165-1781(94)90042-6 · DOI
  56. Neelamekam, 2014, Regulation of interleukin-6 and leptin in schizophrenia patients: a preliminary analysis, Clin Psychopharmacol Neurosci, 12, 209, 10.9758/cpn.2014.12.3.209 · DOI
  57. Barak, 1995, Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients, J Basic Clin Physiol Pharmacol, 6, 61, 10.1515/JBCPP.1995.6.1.61 · DOI
  58. Prasad, 2015, Differential susceptibility of white matter tracts to inflammatory mediators in schizophrenia: an integrated DTI study, Schizophr Res, 161, 119, 10.1016/j.schres.2014.09.043 · DOI
  59. Shintani, 1991, Serum interleukin-6 in schizophrenic patients, Life Sci, 49, 661, 10.1016/0024-3205(91)90112-O · DOI
  60. Kim, 2000, Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics, Schizophr Res, 44, 165, 10.1016/S0920-9964(99)00171-1 · DOI
  61. Hornberg, 1995, Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia, Schizophr Res, 15, 237, 10.1016/0920-9964(94)00046-B · DOI
  62. Borovcanin, 2013, Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response, Schizophr Res, 147, 103, 10.1016/j.schres.2013.03.027 · DOI
  63. Arolt, 1997, Production of interferon-gamma in families with multiple occurrence of schizophrenia, Psychiatry Res, 66, 145, 10.1016/S0165-1781(96)03023-5 · DOI
  64. Arolt, 2000, Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment, Mol Psychiatry, 5, 150, 10.1038/sj.mp.4000650 · DOI
  65. Wilke, 1996, Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients, Eur Arch Psychiatry Clin Neurosci, 246, 279, 10.1007/BF02190280 · DOI
  66. Krause, 2013, Impact of different antipsychotics on cytokines and tryptophan metabolites in stimulated cultures from patients with schizophrenia, Psychiatr Danub, 25, 389
  67. Inglot, 1994, Interferon responses in schizophrenia and major depressive disorders, Biol Psychiatry, 35, 464, 10.1016/0006-3223(94)90045-0 · DOI
  68. Rothermundt, 1996, Production of cytokines in acute schizophrenic psychosis, Biol Psychiatry, 40, 1294, 10.1016/S0006-3223(96)00360-5 · DOI
  69. Moises, 1985, Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients, Acta Psychiatr Scand, 72, 45, 10.1111/j.1600-0447.1985.tb02569.x · DOI
  70. Preble, 1985, Serum interferon in patients with psychosis, Am J Psychiatry, 142, 1184, 10.1176/ajp.142.10.1184 · DOI
  71. Avgustin, 2005, Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia, Croat Med J, 46, 268
  72. Gattaz, 1992, Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected, Schizophr Res, 6, 237, 10.1016/0920-9964(92)90006-Q · DOI
  73. Katila, 1989, Production of interferon-alpha and gamma by leukocytes from patients with schizophrenia, Schizophr Res, 2, 361, 10.1016/0920-9964(89)90028-5 · DOI
  74. Becker, 1990, Serum interferon in first psychotic attack, Br J Psychiatry, 157, 136, 10.1192/bjp.157.1.136 · DOI
  75. Chiang, 2013, Is T-helper type 2 shift schizophrenia-specific? Primary results from a comparison of related psychiatric disorders and healthy controls, Psychiatry Clin Neurosci, 67, 228, 10.1111/pcn.12040 · DOI
  76. Morimoto, 2014, Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort, Int J Obes (Lond), 38, 1416, 10.1038/ijo.2014.25 · DOI
  77. O'Connell, 2014, Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine, Schizophr Res, 156, 1, 10.1016/j.schres.2014.03.020 · DOI
  78. Weiner, 2014, Systemic inflammation and brachial artery endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA), Heart, 100, 862, 10.1136/heartjnl-2013-304893 · DOI
  79. Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, 59, 22
  80. van den Berg, 2012, The Telephone Interview for Cognitive Status (Modified): relation with a comprehensive neuropsychological assessment, J Clin Exp Neuropsychol, 34, 598, 10.1080/13803395.2012.667066 · DOI
  81. Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
  82. Andreasen, 1982, Negative v positive schizophrenia. Definition and validation, Arch Gen Psychiatry, 39, 789, 10.1001/archpsyc.1982.04290070025006 · DOI
  83. Linn, 1968, Cumulative illness rating scale, J Am Geriatr Soc, 16, 622, 10.1111/j.1532-5415.1968.tb02103.x · DOI
  84. Andreasen, 1995, Symptoms of schizophrenia. Methods, meanings, and mechanisms, Arch Gen Psychiatry, 52, 341, 10.1001/archpsyc.1995.03950170015003 · DOI
  85. Fucetola, 2000, Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers, Biol Psychiatry, 48, 137, 10.1016/S0006-3223(00)00240-7 · DOI
  86. Wobrock, 2008, Cognitive impairment of executive function as a core symptom of schizophrenia, World J Biol Psychiatry, 1
  87. Eyre, 2016, A meta-analysis of chemokines in major depression, Prog Neuropsychopharmacol Biol Psychiatry, 68, 1, 10.1016/j.pnpbp.2016.02.006 · DOI · Paper page
  88. Eker, 2014, Can BDNF and IL-2 be indicators for the diagnosis in schizophrenic patients with depressive symptoms?, Acta Neuropsychiatr, 26, 291, 10.1017/neu.2014.13 · DOI
  89. Noto, 2015, Effects of depression on the cytokine profile in drug naive first-episode psychosis, Schizophr Res, 164, 53, 10.1016/j.schres.2015.01.026 · DOI
  90. Smagula, 2016, Immunological biomarkers associated with brain structure and executive function in late-life depression: exploratory pilot study, Int J Geriatr Psychiatry, 10.1002/gps.4512 · DOI
  91. Strawbridge, 2015, Inflammation and clinical response to treatment in depression: a meta-analysis, Eur Neuropsychopharmacol, 25, 1532, 10.1016/j.euroneuro.2015.06.007 · DOI · Paper page
  92. Michaud, 2013, Proinflammatory cytokines, aging, and age-related diseases, J Am Med Dir Assoc, 14, 877, 10.1016/j.jamda.2013.05.009 · DOI · Paper page
  93. Bermudez, 2002, Relation between markers of systemic vascular inflammation and smoking in women, Am J Cardiol, 89, 1117, 10.1016/S0002-9149(02)02284-1 · DOI · Paper page
  94. Helmersson, 2005, Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men, Atherosclerosis, 181, 201, 10.1016/j.atherosclerosis.2004.11.026 · DOI
  95. Bostrom, 1998, Clinical expression of TNF-alpha in smoking-associated periodontal disease, J Clin Periodontol, 25, 767, 10.1111/j.1600-051X.1998.tb02368.x · DOI
  96. Bostrom, 1999, Smoking and crevicular fluid levels of IL-6 and TNF-alpha in periodontal disease, J Clin Periodontol, 26, 352, 10.1034/j.1600-051X.1999.260604.x · DOI
  97. Cesar-Neto, 2006, Smoking modulates interferon-gamma expression in the gingival tissue of patients with chronic periodontitis, Eur J Oral Sci, 114, 403, 10.1111/j.1600-0722.2006.00397.x · DOI
  98. Ouyang, 2000, Suppression of human IL-1beta, IL-2, IFN-gamma, and TNF-alpha production by cigarette smoke extracts, J Allergy Clin Immunol, 106, 280, 10.1067/mai.2000.107751 · DOI
  99. Soliman, 1992, Cigarette smoking decreases bioactive interleukin-6 secretion by alveolar macrophages, Am J Physiol, 263, L471
  100. Mian, 2008, Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke, J Leukoc Biol, 83, 774, 10.1189/jlb.0707481 · DOI
  101. Gaschler, 2008, Cigarette smoke exposure attenuates cytokine production by mouse alveolar macrophages, Am J Respir Cell Mol Biol, 38, 218, 10.1165/rcmb.2007-0053OC · DOI
  102. Kraemer, 2016, Messages for clinicians: moderators and mediators of treatment outcome in randomized clinical trials, Am J Psychiatry, 173, 672, 10.1176/appi.ajp.2016.15101333 · DOI
  103. Kraemer, 2008, Toward non-parametric and clinically meaningful moderators and mediators, Stat Med, 27, 1679, 10.1002/sim.3149 · DOI

Cited by

Sorted by citations

See all 94

Metadata

Authors
Lee, E. E., Hong, S., Martin, A. S., Eyler, L. T., & Jeste, D. V.
Venue
The American Journal of Geriatric Psychiatry
Publisher
Elsevier BV
Published
2017-01
Volume
25
Issue
1
Pages
50-61
ISSN
1064-7481
DOI
10.1016/j.jagp.2016.09.009
PMC
PMC5164855
Cited by
94
References
11
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • National Institutes of Health (R01MH094151-01)
  • National Institute of Mental Health (MH019934)
  • University of California, San Diego

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review